12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Qnexa phentermine/topiramate: Preliminary data

Additionally, the oral cleft prevalence rate in 1,945 mother-infant dyads that were exposed to topiramate either alone or in combination with other anti-epileptic drugs in the first trimester was 0.36%. In a second control group of 13,614 mother-infant dyads who were not exposed to prior anti-epileptic drugs but had similar medical profiles to that of the first trimester topiramate cohort, the prevalence rate was 0.07%. The study is also evaluating major congenital malformations associated with topiramate. Final results from FORTRESS are expected in 3Q12. Topiramate is approved at doses of up to 100 mg/day to treat migraines and 400 mg/day...

Read the full 478 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >